Table 2.

The results of subgroup analyses by factors of medication, time to primary endpoint, and data source

Outcome	Subgroup	No. of studies	No. of patients	OR (95% CI)	P value
Medication
ASAS20	SEC	6	1653	2.54 (2.05, 3.14)	< 0.01
	IXE	2	567	2.47 (1.72, 3.57)	< 0.01
	NET	1	89	5.85 (2.08, 16.47)	< 0.01
ASAS40	SEC	5	1195	2.54 (1.90, 3.41)	< 0.01
	IXE	2	567	3.49 (2.22, 5.48)	< 0.01
AEs	SEC	5	1196	1.20 (0.94, 1.53)	0.15
	IXE	2	567	1.44 (1.01, 2.05)	0.04
	BIM	1	303	0.93 (0.52, 1.66)	0.81
Nasopharyngitis	SEC	5	1196	1.84 (1.16, 2.94)	0.01
	IXE	2	567	1.39 (0.63, 3.06)	0.41
SAEs	SEC	6	1654	0.87 (0.47, 1.61)	0.66
	IXE	2	567	0.86 (0.30, 2.49)	0.78
Time to endpoint
ASAS20	6 weeks	1	29	7.78 (0.78, 77.93)	0.08
	16 weeks	8	2280	2.56 (2.14, 3.07)	< 0.01
ASAS40	6 weeks	1	29	2.19 (0.21, 22.34)	0.51
	16 weeks	6	1733	2.81 (2.19, 3.59)	< 0.01
AEs	6 weeks	1	30	1.21 (0.04, 33.21)	0.91
	12 weeks	1	303	0.93 (0.52, 1.66)	0.81
	16 weeks	6	1733	1.27 (1.04, 1.56)	0.02
Nasopharyngitis	6 weeks	1	30	5.57 (0.28, 112.01)	0.26
	16 weeks	6	1733	1.66 (1.11, 2.50)	0.01
SAEs	6 weeks	1	30	0.83 (0.03, 22.87)	0.91
	16 weeks	7	2191	0.87 (0.51, 1.49)	0.61
Data source
ASAS20	Full text	7	1762	2.55 (2.07, 3.13)	< 0.01
	Conference abstract	2	547	2.70 (1.86, 3.92)	< 0.01
AEs	Full text	7	1763	1.27 (1.04, 1.56)	0.02
	Conference abstract	1	303	0.93 (0.52, 1.66)	0.81
SAEs	Full text	7	1763	0.74 (0.41, 1.33)	0.32
	Conference abstract	1	458	1.69 (0.46, 6.25)	0.43

SEC, secukinumab; IXE, ixekizumab; NTK, netakimab; BIM, bimekizumab